What is 35Pharma?
35Pharma operates as a specialized clinical-stage biopharmaceutical entity focused on the development of innovative therapeutics. The company distinguishes itself through its deep expertise in Activin and GDF biology, utilizing advanced protein engineering to design multi-specific ligand traps. These highly selective molecules are engineered to address significant unmet medical needs, with a primary focus on pulmonary hypertension, heart failure, and obesity. By targeting the TGF-beta superfamily, 35Pharma aims to redefine treatment paradigms for chronic conditions, positioning itself as a high-value player in the competitive landscape of modern biotechnology.
How much funding has 35Pharma raised?
35Pharma has raised a total of $53M across 1 funding round:
Series C
$53M
Series C (2024): $53M with participation from Deep Track Capital, Vivo Capital, and Frazier Life Sciences Management
Key Investors in 35Pharma
Deep Track Capital
Deep Track Capital is an investment firm located in Greenwich, Connecticut, that specializes in the life sciences industry. The firm focuses exclusively on investing in biotechnology.
Vivo Capital
Vivo Capital founded in 1996 and headquartered in Palo Alto, California, is a global healthcare investment firm focused on private and public equity as well as venture capital.
Frazier Life Sciences Management
Frazier Life Sciences is a longstanding biotech investment firm that employs both venture and public strategies to partner with and build companies focused on developing novel therapeutics.
What's next for 35Pharma?
With the recent capital injection, 35Pharma is poised to scale its clinical development operations significantly. The strategic roadmap involves accelerating the trial progression for HS235, moving toward critical data readouts that will validate the efficacy of its ligand trap platform. As the company transitions into more advanced clinical stages, the focus will likely shift toward optimizing manufacturing processes and exploring potential strategic partnerships to broaden the therapeutic application of its pipeline. The firm remains committed to delivering transformative outcomes for patients, supported by a robust balance sheet and a clear mandate for scientific innovation in the biopharmaceutical sector.
See full 35Pharma company page
